MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy
Cancer Drug Resistance · 10.12.2025
DOI: 10.20517/cdr.2025.146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 10.12.2025. Verfasst von Michael Attathikhun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer therapy remains an active field of investigation, particularly in understanding and overcoming therapy resistance. Small non-coding RNAs, such as microRNAs (miRNAs), are emerging as key regulators of cancer survival, progression, proliferation, invasion, migration, and metastasis. Although many studies have linked miRNAs to cancer therapy outcomes, significant questions remain regarding their precise molecular and cellular roles in therapy resistance. Increasing evidence shows that miRNAs influence critical pathways such as apoptosis, immune evasion, and other signaling cascades. However, there have been many setbacks because of the limitations in knowledge of each specific miRNA’s function. A deeper understanding of miRNA expression and function may enhance the development of more effective cancer therapeutics and improve overall survival of patients. This review explores the role of miRNA expression as a key regulator of therapeutic resistance in cancer patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Attathikhun, M., Jurj, A., & Calin, G. A. (2025). MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.146
Vancouver
Attathikhun M, Jurj A, Calin GA. MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2025.146
BibTeX
@article{Attathikhun2025,
author = {Attathikhun, Michael and Jurj, Ancuta and Calin, George A},
title = {MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy},
journal = {Cancer Drug Resistance},
year = {2025},
doi = {10.20517/cdr.2025.146}
}
EUVIMED